REFERENCES
1. Porter MJ, Morton JB, Denman R, et al. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm. 2004;1:393-396.
2. Page RL, Joglar JA, Caldwell MA, et al.
2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. JAm Coll Cardiol. 2016;67:e27-e115.3. Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36:2242-2246.
4. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. J Am Med Assoc. 1994;271:840-844.
5. Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49:565-571.
6. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.
7. Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51:828-835.
8. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensinconverting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-1839.
9. Baker WL, White CM. Post-cardiothoracic surgery atrial fibrillation: a review of preventive strategies. Ann Pharmacother. 2007;41:587-598.
10. Van Gelder IC, Hagens VE, Bosker HA, et al.
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. NEngl J Med. 2002;347:1834-1840.11. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
12. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, Aecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. NEngl J Med. 1991;324:781- 788.
13. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation. 1990;82:51-59.
14. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82:1545-1547, A8.
15. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary. A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15:e190-e252.
16. Tchou P, Young P, Mahmud R, et al. Useful clinical criteria for the diagnosis of ventricular tachycardia. Am J Med. 1988;84:53-56.
17. Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. NEngl J Med. 1997;337:1576-1583.
18. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial (MADIT) Investigators. NEngl J Med. 1996;335:1933-1940.
19.
Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882-1890.20. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEngl J Med. 2002;346:877-883.
21. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. NEngl J Med. 2002;346:884-890.
22. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2:823-827.
23. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
24. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001- 2007.
25. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left- ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
26. Ajijola OA, Lellouche N, Bourke T, et al. Bilateral cardiac sympathetic denervation for the management of electrical storm. J Am Coll Cardiol. 2012;59(1):91-92.
27. Cuculich PS, Schill MR, Kashani R, et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia. NEngl JMed. 2017;377:2325-2336.
28. Strickberger SA, Benson DW, Biaggioni I, et al. AHA/ACCF scientific statement on the evaluation of syncope from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: in collaboration with the Heart Rhythm Society.
Circulation. 2006;113:316-327.29. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. NEngl J Med. 2002;347:878-885.
30. Chen L, Chen MH, Larson MG, et al. Risk factors for syncope in a community-based sample (the Framingham Heart Study). Am J Cardiol. 2000;85:1189-1193.
31. Linzer M, Yang EH, Estes NA III, et al. Diagnosing syncope. Part 1: value of history, physical examination, and electrocardiography. Clinical efficacy assessment project of the American College of Physicians. Ann Intern Med. 1997;126:989-996.
32. Linzer M, Yang EH, Estes NA III, et al. Diagnosing syncope. Part 2: unexplained syncope. Clinical efficacy assessment project of the American College of Physicians. Ann Intern Med. 1997;127:76- 86.
33. Sheldon R, Connolly S, Rose S, et al. Prevention of Syncope Trial (POST): a randomized, placebo- controlled study of metoprolol in the prevention of vasovagal syncope. Circulation. 2006;113:1164-1170.
34. Samniah N, Sakaguchi S, Lurie KG, et al. Efficacy and safety of midodrine hydrochloride in patients with refractory vasovagal syncope. Am J Cardiol. 2001;88:A7, 80-83.
35. Kuriachan V, Sheldon RS, Platonov M. Evidence-based treatment for vasovagal syncope. Heart Rhythm. 2008;5:1609-1614.
36. Connolly SJ, Sheldon R, Thorpe KE, et al. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncopesecond Vasovagal Pacemaker Study (VPS II): a randomized trial. J Am Med Assoc. 2003;289:2224-2229.